Author

Yaping Wu

ORCID 0000-0002-5133-4698Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1 Assay:imaging· 1 Organism:mouse· 1

Frequent Co-Authors

Brady M. BernardiD· 1 shared Brian PieningiD· 1 shared David G. KirschiD· 1 shared Eric S. XuiD· 1 shared Jianguo HuangiD· 1 shared John T. Welle· 1 shared Lixia LuoiD· 1 shared Melissa J. Kasiewicz· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Brady M. BernardORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of soft tissue sarcoma

Jianguo Huang, Xingliang Liu, Warren Floyd, William Haugh, Zhaoyu Sun, Melissa J. Kasiewicz, Yaping Wu, Brian Piening, John T. Welle, Wesley K. Rosales, Venkatesh Rajamanickam, So Young Kim, Eric S. Xu, Lixia Luo, Yan Ma, , David G. Kirsch

The paper identifies BAP1 as a tumor suppressor in soft tissue sarcoma using an in vivo CRISPR screen and shows that PLK1 inhibition can suppress tumor growth in BAP1-deficient models.

bioRxiv · Dec 5, 2025 · PreprintCancer Biology